Details

Autor(en) / Beteiligte

• Clemmensen, Stine N.
• Glenthøj, Anders J.
• Heebøll, Sara
• Nielsen, Hans Jørgen
• Koch, Claus
• Borregaard, Niels

Titel

Plasma levels of OLFM 4 in normals and patients with gastrointestinal cancer

Ist Teil von

• Journal of cellular and molecular medicine, 2015-12, Vol.19 (12), p.2865-2873

Ort / Verlag

Chichester: John Wiley & Sons, Inc

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Abstract Olfactomedin 4 ( OLFM 4) is a secreted glycoprotein predominantly expressed in bone marrow and gastrointestinal tissues. Aberrant expression of OLFM 4 has been shown in several cancers. However, the clinical significance hereof is currently controversial. OLFM 4 has been proposed as a candidate biomarker of gastrointestinal cancers. To address this, we developed monoclonal antibodies against synthetic peptides representing various segments of OLFM 4. We examined expression of OLFM 4 in epithelial cells by immunohistochemistry and found that OLFM 4 is highly expressed in proliferating benign epithelial cells and in some carcinoma cells. We developed an Enzyme Linked Immunosorbent Assay for OLFM 4 and investigated whether plasma levels of OLFM 4 reflect colorectal malignancies, but were unable to see any such association. Instead, we observed two populations of individuals with respect to OLFM 4 levels in plasma, the majority with OLFM 4 in plasma between 0 and 0.1 μg/ml, mean 0.028 μg/ml while 10% of both normals and patients with cancers had OLFM 4 between 4 and 60 μg/ml, mean 15 μg/ml. The levels were constant over time. The background for this high plasma level is not known, but must be taken into account if OLFM 4 is used as biomarker for GI cancers.